Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169362 | 0.95 | LMNA (0.73) | TSHRSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL18501704 | 0.83 | POLB (0.68) | SMN1; SMN2KMT2AMEN1LMNAGAA | |
| SCHEMBL17194214 | 0.82 | KMT2A (0.77) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL13202848 | 0.82 | SMN1; SMN2 (1.00) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL4402433 | 0.82 | LMNA (0.90) | KMT2AMEN1HTTLMNAGAA | |
| SCHEMBL12169363 | 0.82 | LMNA (0.96) | KMT2AMEN1LMNAGAAPOLB | |
| SCHEMBL26970150 | 0.81 | ALDH1A1 (0.70) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL9906448 | 0.80 | LMNA (1.00) | KMT2AMEN1HTTLMNAGAA | |
| SCHEMBL4555408 | 0.80 | LMNA (1.00) | KMT2AMEN1HTTLMNAGAA | |
| SCHEMBL14349446 | 0.80 | ATM (0.58) | TSHRSMN1; SMN2KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | TSHR 4263/4885SMN1; SMN2 4030/4885KMT2A 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.